Salt Lake City, UT, March 10, 2018 --(PR.com
)-- Aciont Inc. announced today that Dr. Kongnara Papangkorn, VP of Product Development, will be presenting clinical data of Aciont’s lead product, DSP-Visulex, from its phase 1/2 clinical trial in the treatment of noninfectious anterior uveitis (DSPV-201) at the Association for Research in Vision and Ophthalmology (ARVO) 2018 annual meeting taking place April 29-May 3 in Honolulu, HI.
Dr. Papangkorn was a key study investigator for the clinical trial. "I am honored to present our clinical results of DSP-Visulex from both its safety and efficacy standpoints to this specialized audience in the fields of ophthalmology,” Papangkorn said.
The study findings suggest that “4 or 5 doses of DSP-Visulex provided the same efficacy results to the standard of care, prednisolone acetate with 112 drops, without any signs of IOP elevation,” Papangkorn said. “DSP-Visulex treatments appear to be safe and well tolerated. The feedback from ophthalmologists involved in this study about the DSP Visulex approach have been positive. I believe this product will ensure a greater compliance to treat the uveitis condition,” Papangkorn added.
This presentation (#5953) will be on Thursday, May 3rd at Room 301AB as part of the Advances in Clinical Therapeutics for Uveitis Session from 11:00 AM to 12:45 PM. The ARVO meeting will be at Hawaii Convention Center in Honolulu and the meeting information can be found at the ARVO website: https://www.arvo.org/annual-meeting/
Aciont Presenting at Other Meetings in March 2018
Aciont will be one of three emerging companies showcased at the 10th Ocular Diseases Drug Discovery Conference organized by GTCbio is scheduled for March 20-21, 2018 in San Diego, CA. John Higuchi will be presenting Aciont's story on Day 2 of the event, March 21 around 12:55 PM. Dr. Balbir Brar will be participating during a special panel discussion on regulatory topics starting earlier in the day at 9:20 AM. The meeting information can be accessed at: https://www.gtcbio.com/conferences/ocular-diseases-drug-discovery/
Aciont is presenting and participating at a cross border investment banking conference in Hangzhou, China, March 15-17, 2018. The conference is sponsored by B. Riley FBR, a preeminent U.S. based investment bank has partnered with TPP Healthcare, the top China business development firm, to bring you the largest gathering of healthcare centric companies and investors to date. They will be hosting 50+ Western healthcare companies (including Aciont Inc.) specializing in innovative technologies in areas that are vital to the growing Chinese healthcare industry, along with over 300+ Chinese healthcare strategic partners and investors. The meeting information can be accessed at: https://www.meetmax.com/sched/event_47969/~public/__agenda_cp.html
About DSP Visulex
DSP-Visulex is a noninvasive drug delivery system of dexamethasone sodium phosphate (DSP). It utilizes a combination of a proprietary high concentration DSP solution and Visulex-P drug applicator technology to enable a simple administration of DSP to treat inflammation conditions of both anterior and posterior eye tissues. Visulex-P is based on passive diffusion to deliver small molecules such as most generic corticosteroids and immunosuppressive agents whereas Visulex-I, its complementary technology for macromolecule delivery, is based on electroosmosis which employs ocular iontophoresis.
DSPV-201 is a multicenter, randomized, parallel group, double-masked, active-controlled study of DSP-Visulex in noninfectious anterior uveitis patients. DSP-Visulex therapy (two applications on the first week then weekly after) was compared to daily prednisolone acetate 1% eye drops. The study was supported by two phase 2 NEI SBIRs, reference by Grant R44EY014772, and the clinical study is registered at clinicaltrials.gov under identifier NCT02309385.
Aciont Inc. is a mid-clinical staged, specialty biopharmaceutical company located in Salt Lake City, Utah. Our Visulex noninvasive drug delivery technology platforms endeavor to advance therapeutics in ophthalmology. Our world-renowned research team is focused on developing noninvasive therapeutics for sight threatening diseases affecting both the anterior and posterior sections of the eye addressing a potential wide range of ocular diseases and drug transport challenges. Our lead clinical staged product, DSP Visulex, addresses key ocular inflammation related indications such as severe uveitis, post-operative pain/inflammation and macular edema.
615 Arapeen Dr., Ste. #302
Salt Lake City, UT 84108